DCM
ELDN icon

Defilade Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Defilade Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Sell
3,525,338
-38,789
-1% -$141K 1.86% 23
2026
Q1 		$11M Buy
3,564,127
+273,677
+8% +$645K 1.54% 28
2025
Q4 		$4.97M Buy
+3,290,450
New +$7.82M 0.67% 31

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Defilade Capital Management's ELDN Position: Q2 2026 in Review

Defilade Capital Management reduced its Eledon Pharmaceuticals (ELDN) stake by 1.1% in Q2 2026, selling an estimated $141K and leaving 3,525,338 shares worth $13.9M. The position accounts for 1.86% of the portfolio, ranked #23.

Defilade Capital Management first reported a position in ELDN in Q4 2025 and has held it in 3 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Defilade Capital Management held 3,525,338 shares of Eledon Pharmaceuticals worth $13.9M as of Q2 2026.
  • Defilade Capital Management sold 38,789 Eledon Pharmaceuticals shares in Q2 2026, an estimated $141K.
  • Eledon Pharmaceuticals made up 1.86% of Defilade Capital Management's portfolio in Q2 2026, its #23 holding.
  • Defilade Capital Management first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.